Congestive heart failure ACE inhibitors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 12: | Line 12: | ||
2. There is a prior history of [[myocardial infarction]] ([[MI]]) | 2. There is a prior history of [[myocardial infarction]] ([[MI]]) | ||
==Background== | ===Background=== | ||
*ACE-I or ARB therapy is recommended for '''ANY''' patient with reduced [[left ventricular ejection fraction]] (≤ 40%) regardless of the etiology of left ventricular systolic dysfunction (ischemic or nonischemic) or presence/absence of symptoms. Patients with or without heart failure (in other words, even those with asymptomatic left ventricular systolic dysfunction) are included in this recommendation. | *ACE-I or ARB therapy is recommended for '''ANY''' patient with reduced [[left ventricular ejection fraction]] (≤ 40%) regardless of the etiology of left ventricular systolic dysfunction (ischemic or nonischemic) or presence/absence of symptoms. Patients with or without heart failure (in other words, even those with asymptomatic left ventricular systolic dysfunction) are included in this recommendation. | ||
*In addition, ACE-I/ARB therapy is indicated for patients with history of myocardial infarction whether or not left ventricular systolic dysfunction or heart failure is present. | *In addition, ACE-I/ARB therapy is indicated for patients with history of myocardial infarction whether or not left ventricular systolic dysfunction or heart failure is present. | ||
*ACE-I or ARB therapy is also recommended for patients who are at high risk for the development of heart failure due to the presence of coronary, cerebrovascular, or peripheral vascular disease. | *ACE-I or ARB therapy is also recommended for patients who are at high risk for the development of heart failure due to the presence of coronary, cerebrovascular, or peripheral vascular disease. | ||
* Treatment should not be deferred in patients with few or no symptoms because of the significant mortality benefit derived from [[Angiotensin converting enzyme inhibitor|ACEI]] therapy. | * Treatment should not be deferred in patients with few or no symptoms because of the significant mortality benefit derived from [[Angiotensin converting enzyme inhibitor|ACEI]] therapy. | ||
==Dosing== | ===Dosing=== | ||
* ACE-I/ARB therapy should be initiated at low dosage such as 12.5 mg tid of [[captopril]], 2.5 mg bid of [[enalapril]], or 2.5 mg daily lisinopril. | * ACE-I/ARB therapy should be initiated at low dosage such as 12.5 mg tid of [[captopril]], 2.5 mg bid of [[enalapril]], or 2.5 mg daily lisinopril. | ||
* Every 4 to 6 weeks the dose is gradually uptitrated, as tolerated, toward target dosages of 20-40 mg daily for lisinopril, 10-20 mg twice daily for enalapril maleate, and 50-100 mg three times a day for captopril, or to the maximum tolerated dosage. | * Every 4 to 6 weeks the dose is gradually uptitrated, as tolerated, toward target dosages of 20-40 mg daily for lisinopril, 10-20 mg twice daily for enalapril maleate, and 50-100 mg three times a day for captopril, or to the maximum tolerated dosage. | ||
* ACE inhibitors are rarely adequate for the treatment of congestion without the use of [[diuretics]]. | * ACE inhibitors are rarely adequate for the treatment of congestion without the use of [[diuretics]]. | ||
===Complications of ACE Inhibitors=== | |||
==Complications of ACE Inhibitors== | |||
* 5-10 % patients cannot tolerate [[ACE inhibitors]] because of [[cough]]. [[Cough]] can be a sign of elevated left-sided filling pressures or a side effect of ACE inhibitors due to excess [[bradykinin]]. | * 5-10 % patients cannot tolerate [[ACE inhibitors]] because of [[cough]]. [[Cough]] can be a sign of elevated left-sided filling pressures or a side effect of ACE inhibitors due to excess [[bradykinin]]. | ||
*ARBs are reserved for patients who are intolerant of ACE-Is for reasons (such as persistent cough) '''''OTHER''''' than [[hyperkalemia]], progression of chronic kidney disease/worsening [[azotemia]], or [[hypotension]] caused by prior ACE-I therapy. If a patient experiences [[hyperkalemia]], worsening [[azotemia]], or [[hypotension]] as a result of [[ACE]]-I therapy, the same is likely to result from [[ARB]] therapy. In the CHARM study [[candesartan]] reduced both hospitalization and mortality. | *ARBs are reserved for patients who are intolerant of ACE-Is for reasons (such as persistent cough) '''''OTHER''''' than [[hyperkalemia]], progression of chronic kidney disease/worsening [[azotemia]], or [[hypotension]] caused by prior ACE-I therapy. If a patient experiences [[hyperkalemia]], worsening [[azotemia]], or [[hypotension]] as a result of [[ACE]]-I therapy, the same is likely to result from [[ARB]] therapy. In the CHARM study [[candesartan]] reduced both hospitalization and mortality. | ||
| Line 57: | Line 56: | ||
==Background== | ==Background== | ||
* Aldosterone antagonist therapy is recommended for patients with advanced heart failure (NYHA class III or IV) and left ventricular systolic dysfunction (LVEF ≤ 35%), who are already receiving optimal medical therapy including loop diuretics, beta blockers and ACE-I/ARBs. | |||
Aldosterone antagonist therapy is recommended for patients with advanced heart failure (NYHA class III or IV) and left ventricular systolic dysfunction (LVEF ≤ 35%), who are already receiving optimal medical therapy including loop diuretics, beta blockers and ACE-I/ARBs. In patients with diabetes mellitus or prior myocardial infarction, the LVEF below which this recommendation applies is 40%. However, patients with baseline renal insufficiency (creatinine > 2.5 mg/dl or creatinine clearance < 30 ml/min), hyperkalemia (K > 5.0 mmol/liter), or who are unlikely to be available for frequent monitoring of renal function and electrolytes should NOT receive an aldosterone antagonist. Other potassium-sparing diuretics (such as triamterene) should not be administered concomitantly with an aldosterone antagonist. | * In patients with diabetes mellitus or prior myocardial infarction, the LVEF below which this recommendation applies is 40%. | ||
* In addition, the EMPHASIS-HF trial showed that [[eplerenone]] at a dose of 25-50mg daily reduced mortality and HF hospitalizations in patients with NYHA class I or II HF and should now be considered in these patients. This is not yet an AHA guideline but should be considered in this group of patients based on the available evidence. | |||
===Contraindications=== | |||
* However, patients with baseline renal insufficiency (creatinine > 2.5 mg/dl or creatinine clearance < 30 ml/min), hyperkalemia (K > 5.0 mmol/liter), or who are unlikely to be available for frequent monitoring of renal function and electrolytes should NOT receive an aldosterone antagonist. Other potassium-sparing diuretics (such as triamterene) should not be administered concomitantly with an aldosterone antagonist. | |||
==References== | ==References== | ||
Revision as of 01:05, 4 April 2012
Editor(s)-In-Chief: James Chang, M.D., Cardiovascular Division Beth Israel Deaconess Medical Center, Boston MA, Harvard Medical School [1] and C. Michael Gibson, M.S., M.D. [2], Cardiovascular Division Beth Israel Deaconess Medical Center, Boston MA, Harvard Medical School
Overview
Indications for an ACE Inhibitor or ARB
1. The left ventricular ejection fraction (LVEF) is ≤ 40%
or
2. There is a prior history of myocardial infarction (MI)
Background
- ACE-I or ARB therapy is recommended for ANY patient with reduced left ventricular ejection fraction (≤ 40%) regardless of the etiology of left ventricular systolic dysfunction (ischemic or nonischemic) or presence/absence of symptoms. Patients with or without heart failure (in other words, even those with asymptomatic left ventricular systolic dysfunction) are included in this recommendation.
- In addition, ACE-I/ARB therapy is indicated for patients with history of myocardial infarction whether or not left ventricular systolic dysfunction or heart failure is present.
- ACE-I or ARB therapy is also recommended for patients who are at high risk for the development of heart failure due to the presence of coronary, cerebrovascular, or peripheral vascular disease.
- Treatment should not be deferred in patients with few or no symptoms because of the significant mortality benefit derived from ACEI therapy.
Dosing
- ACE-I/ARB therapy should be initiated at low dosage such as 12.5 mg tid of captopril, 2.5 mg bid of enalapril, or 2.5 mg daily lisinopril.
- Every 4 to 6 weeks the dose is gradually uptitrated, as tolerated, toward target dosages of 20-40 mg daily for lisinopril, 10-20 mg twice daily for enalapril maleate, and 50-100 mg three times a day for captopril, or to the maximum tolerated dosage.
- ACE inhibitors are rarely adequate for the treatment of congestion without the use of diuretics.
Complications of ACE Inhibitors
- 5-10 % patients cannot tolerate ACE inhibitors because of cough. Cough can be a sign of elevated left-sided filling pressures or a side effect of ACE inhibitors due to excess bradykinin.
- ARBs are reserved for patients who are intolerant of ACE-Is for reasons (such as persistent cough) OTHER than hyperkalemia, progression of chronic kidney disease/worsening azotemia, or hypotension caused by prior ACE-I therapy. If a patient experiences hyperkalemia, worsening azotemia, or hypotension as a result of ACE-I therapy, the same is likely to result from ARB therapy. In the CHARM study candesartan reduced both hospitalization and mortality.
- Renal artery stenosis should be considered if there's a decline in renal function with the initiation of ACE inhibitors.
Indications for Aldosterone Antagonists
A patient should be on an aldosterone antagonist if:
1. The potassium (K) is ≤ 5.0 mmol/liter
and
2. The creatinine (Cr) is ≤ 2.5 mg/dl
and
3. The left ventricular ejection fraction (LVEF) is ≤ 35%
OR
1. The potassium (K) is ≤ 5.0 mmol/liter
and
2. The creatinine (Cr) is ≤ 2.5 mg/dl
and
3. The left ventricular ejection fraction (LVEF is ≤ 40%
and
4. There is a history of prior myocardial infarction (MI)
Background
- Aldosterone antagonist therapy is recommended for patients with advanced heart failure (NYHA class III or IV) and left ventricular systolic dysfunction (LVEF ≤ 35%), who are already receiving optimal medical therapy including loop diuretics, beta blockers and ACE-I/ARBs.
- In patients with diabetes mellitus or prior myocardial infarction, the LVEF below which this recommendation applies is 40%.
- In addition, the EMPHASIS-HF trial showed that eplerenone at a dose of 25-50mg daily reduced mortality and HF hospitalizations in patients with NYHA class I or II HF and should now be considered in these patients. This is not yet an AHA guideline but should be considered in this group of patients based on the available evidence.
Contraindications
- However, patients with baseline renal insufficiency (creatinine > 2.5 mg/dl or creatinine clearance < 30 ml/min), hyperkalemia (K > 5.0 mmol/liter), or who are unlikely to be available for frequent monitoring of renal function and electrolytes should NOT receive an aldosterone antagonist. Other potassium-sparing diuretics (such as triamterene) should not be administered concomitantly with an aldosterone antagonist.